Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 15Esophageal Neoplasms 12Colorectal Neoplasms 9Stomach Neoplasms 6Rectal Neoplasms 6Esophageal Squamous Cell Carcinoma 6Pancreatic Neoplasms 5Neoplasms 4Liver Neoplasms 4Cholangiocarcinoma 4Neoplasm Metastasis 3Melanoma 3Carcinoma, Renal Cell 3Liver Diseases 2Gastrointestinal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Adenocarcinoma 2Waldenstrom Macroglobulinemia 1Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Unresectable Hepatocellular Carcinoma 1Unresectable Biliary Tract Cancer 1Triple Negative Breast Neoplasms 1Tongue Neoplasms 1Thyroid Neoplasms 1

Interventions

Oxaliplatin 2tislelizumab 1sintilimab 1donafenib 1Immunotherapy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Biliary Tract Carcinoma × Immunotherapy × Gastrointestinal × Clear all
NCT06199882 2024-10-15

SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract Carcinoma

Zhejiang Cancer Hospital

Phase 2 Suspended
34 enrolled
Gastrointestinal

Biliary Tract Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡